NEW GLAUCOMA DRUGS ADDED TO TREATMENT ARSENAL

0

Last year saw the introduction of two glaucoma drugs. Both work to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Here are some facts you need before you prescribe them.

VYZULTA | Bausch + Lomb, 800.828.9030, Bausch.com
Generic: latanoprostene bunod ophthalmic solution 0.024%,
Dosage: One drop in the affected eye(s) once daily in the evening.
Possible side effects:
• Brown color, or increased brown color, of the iris that may be permanent.
• Darkening of the eyelid skin, which is usually reversible after treatment is discontinued.
• Gradual changes to eyelashes, including increased length, thickness, color, number of eyelashes and/or direction of eyelash growth. These changes are usually reversible after treatment is discontinued.
• Most common ocular adverse effects: conjunctival hyperemia, eye irritation, eye pain, and pain at the instillation site.
What B+L wants you to know:
• VYZULTA provides consistent and sustained IOP lowering.
• VYZULTA works by metabolizing into two moieties: latanoprost acid and butanediol mononitrate. Latanoprost acid, an F2α prostaglandin analog, primarily works within the uveoscleral pathway to increase aqueous humor outflow. Butanediol mononitrate releases nitric oxide to increase outflow through the trabecular meshwork and Schlemm’s canal.
• The safety and efficacy of VYZULTA is supported by published clinical studies.

RHOPRESSA | Aerie Pharmaceuticals, Inc., 919.237.5300, Rhopressa.com
Generic: netarsudil ophthalmic solution 0.02%
Dosage: One drop in the affected eye(s) once daily in the evening.
Possible side effects:
• The most common ocular adverse effect was conjunctival hyperemia.
• Other common effects: corneal verticillata, instillation site pain, and conjunctival hemorrhage. The majority of these ocular adverse effects were mild.
What Aerie Pharmaceuticals wants you to know:
• Rhopressa is the first FDA-approved Rho kinase (ROCK) inhibitor. It represents the first new class of IOP-lowering medications in 20 years.
• Rhopressa targets a main cause of elevated IOP. It is believed to work at the cellular level within the trabecular meshwork to improve outflow of aqueous humor.
• Rhopressa produces consistent IOP reductions across a range of baseline pressures.
• Once-daily dosing with Rhopressa simplifies the treatment regimen.
• Rhopressa has minimal systemic adverse events and no contraindications.
• Rhopressa will be available in spring 2018.

Share.

Leave A Reply